Vaxcyte, Inc.
PCVX
Classificação em ações
#2074
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Preço da ação
$63.69
Valor de mercado
$10.02B
Variação (1 dia)
-3.84%
Variação (1 ano)
50.39%
País
US
Negociar Vaxcyte, Inc. (PCVX)
Categoria
Healthcare
Histórico de preços das ações de Vaxcyte, Inc. (PCVX)
Preço de fecho mais alto: $65.59 em 2026-10-01
Preço de fecho mais baixo: $32.16 em 2020-06-01
Preço de fecho mais baixo: $32.16 em 2020-06-01
Histórico de preços das ações da Vaxcyte, Inc. de 2020 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | 18.84% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $518.36 | 21.60% |
US
|
|
| $248.70 | 804.69% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $886.11 | 6.15% |
NL
|
|
| $752.87 | 7.40% |
CH
|
